Aurora Therapeutics Scraps Lead Program After Seven Months
Aurora Therapeutics has scrapped its lead program and slashed its workforce. The abrupt strategic retreat comes just seven months after the startup launched to build personalized gene-editing drugs.
Undeclared Layoffs and Leadership Departures
A company spokesperson declined to disclose how many employees were affected by the layoffs, according to reports verified by industry publications.
It remains unconfirmed whether any members of the startup’s three-person leadership team will remain with the organization. Public filings and corporate updates indicate that the company’s chief scientific officer also departed earlier this year.
Rival Beam Therapeutics Targets Identical Genetic Disease
The swift reversal appears to stem from intense market pressures and rapid advancements by larger rivals.
Just one month after Aurora Therapeutics formally launched, Beam Therapeutics announced it was already advancing its own proprietary suite of custom gene editors aimed at the exact same genetic disease.
Scaling Custom CRISPR Therapies Against Deep Pockets
Aurora Therapeutics entered the market with ambitions to scale custom CRISPR therapies tailored to individual patient mutations.
Beam Therapeutics, a publicly traded gene-editing pioneer utilizing base-editing technology, moved aggressively into the same therapeutic space shortly after Aurora’s public unveiling.
An Uncertain Future Amid Tightening Venture Capital
Related reading